# Gossamer Bio, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Gossamer Bio, Inc.). ## Overview Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing seralutinib, an inhaled therapy candidate for pulmonary arterial hypertension and related cardiopulmonary diseases. The company currently has no product sales and is funded primarily through collaboration revenue, equity financing, and other capital sources while it advances development and prepares for potential commercialization. ## Products & services • Seralutinib clinical development for pulmonary hypertension • Collaboration-based R&D services under the Chiesi agreement • Worldwide license and commercialization rights for seralutinib • Pre-commercial and regulatory development activities - **Seralutinib development** (0%) — Clinical and preclinical development of seralutinib, the company's lead inhaled therapy candidate. - **Collaboration revenue** (100%) — Cost reimbursement and cost-sharing payments from the Chiesi collaboration. - **License and milestone economics** (0%) — Upfront, regulatory, commercial milestone, and royalty economics tied to the Chiesi partnership. - **Future product sales** (0%) — Potential direct sales of seralutinib if regulatory approval and commercialization are achieved. - Seralutinib clinical development for pulmonary arterial hypertension - Research and development services under the Chiesi collaboration - Worldwide licensing of seralutinib and licensed products - Pre-commercial regulatory and manufacturing planning - Potential future commercialization of seralutinib ## Customers Gossamer Bio does not currently sell approved products to end customers; its current revenue comes from Chiesi under a global collaboration. If seralutinib is approved, the company would serve patients with pulmonary arterial hypertension and other cardiopulmonary diseases through physicians, hospitals, and specialty pharmacies, with commercialization split across the U.S. and ex-U.S. territories. - **Chiesi collaboration partner** (primary) — Chiesi funds shared development and commercialization economics under the global seralutinib agreement. - **Pulmonary arterial hypertension patients** (primary) — Future patients who may receive seralutinib if it is approved for PAH and related indications. - **Specialist prescribers** (secondary) — Pulmonologists, cardiologists, and specialty centers that would prescribe and monitor therapy. - **Payers and reimbursement authorities** (secondary) — Insurers, government programs, and HTA bodies that determine access and pricing after approval. - Chiesi is the current collaboration counterparty funding development work - Patients with pulmonary arterial hypertension are the future end market - Specialist physicians would prescribe seralutinib if approved - Hospitals and specialty pharmacies would support access and distribution - Payers and HTA bodies would influence pricing and reimbursement ## Geography The company is headquartered in the United States and its current operations are centered on U.S.-based clinical development and corporate functions. Through the Chiesi agreement, seralutinib has worldwide development and commercialization rights, creating exposure to U.S. and ex-U.S. regulatory, pricing, and reimbursement regimes. - United States is the core operating base and current revenue source - Worldwide rights are covered by the Chiesi collaboration - U.S. commercialization economics are shared with Chiesi - Ex-U.S. sales would generate royalties in the mid-to-high teens - EU pricing and HTA rules could affect future commercialization ## Strategy The company's near-term strategy is to advance seralutinib through Phase 3 development while managing cash burn and preserving optionality for future commercialization. The Chiesi partnership is central to this plan because it shares development costs, provides non-dilutive funding, and creates a pathway to global launch if the asset succeeds. - **Complete seralutinib Phase 3 development** (short-term) — Clinical success is the main value driver and prerequisite for approval and commercialization. - **Leverage the Chiesi collaboration** (short-term) — The partnership reduces funding needs and shares commercialization risk. - **Maintain financing flexibility** (short-term) — The company has no product revenue and may need additional capital before approval. - **Build a path to commercialization** (medium-term) — Approval would require manufacturing, distribution, and market access capabilities. - Advance seralutinib through Phase 3 clinical development - Use the Chiesi partnership to share development and launch costs - Preserve cash by limiting spend on non-core programs - Prepare manufacturing, regulatory, and commercialization capabilities - Seek non-dilutive funding and capital flexibility ## Risks Gossamer Bio is exposed to clinical, regulatory, and financing risk because its value depends heavily on a single lead asset that is still in development. Future commercialization also depends on payer access, pricing pressure, and cross-border regulatory frameworks, while the company may need to raise additional capital before it can generate meaningful product revenue. - **Clinical development failure for seralutinib** [critical] — The company has no approved products and depends on one lead candidate for future value creation. - **Financing and liquidity risk** [high] — Current revenue is collaboration-based and may not support the cost structure before approval. - **Pricing and reimbursement pressure** [high] — State drug pricing rules, hospital bidding, and payer controls can reduce net realized pricing. - **Regulatory and HTA delays** [medium] — EU HTA and national reimbursement decisions can delay or constrain market access. - **Trade and supply chain disruption** [medium] — Tariffs, export controls, and import/export changes can affect development and commercialization logistics. - Seralutinib may fail in clinical trials or not win approval - The company may need additional capital before commercialization - Pricing and reimbursement pressure could limit future sales - Regulatory changes in the U.S. and EU may slow launch timing - Trade and import/export rules could disrupt development or supply ## Accounting Revenue recognition is driven by the Chiesi collaboration and includes a one-time license reimbursement payment plus ongoing cost-sharing for R&D and pre-commercial services, so quarterly revenue can be uneven and contract-specific. Investors should also watch expense recognition for clinical trials and in-process R&D, since development costs are expensed as incurred and can move materially with trial timing and program decisions. - **Collaboration revenue recognition** — Can create large period-to-period swings in reported revenue - **Clinical trial expense timing** — Directly affects operating loss and cash burn - **In-process R&D expensing** — Can create one-time operating expense spikes - **Stock-based compensation** — Affects operating expenses and non-cash dilution - Collaboration revenue recognition depends on license and cost-sharing terms - Clinical trial timing creates quarter-to-quarter revenue and expense volatility - In-process R&D is expensed immediately when acquired or in-licensed - Stock-based compensation affects G&A and R&D expense levels - Cash, marketable securities, and debt-related items affect other income/expense --- *Last updated: 2026-04-28T20:11:54.614886+00:00*